

Sorrento Therapeutics, Inc.  
Form 8-K  
April 13, 2015

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 13, 2015**

**SORRENTO THERAPEUTICS, INC.**

**(Exact name of registrant as specified in its charter)**

<b>Delaware</b> <b>(State or other jurisdiction</b>	<b>001-36150</b> <b>(Commission</b>	<b>33-0344842</b> <b>IRS Employer</b>
<b>of incorporation or organization)</b>	<b>File Number)</b> <b>6042 Cornerstone Ct. West, Suite B</b>	<b>Identification No.)</b>
	<b>San Diego, CA 92121</b>	

Edgar Filing: Sorrento Therapeutics, Inc. - Form 8-K

**(Address of principal executive offices)**

**Registrant's telephone number, including area code: (858) 210-3700**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Items.**

On April 13, 2015, Sorrento Therapeutics, Inc. (the Company ) issued a press release announcing that Dr. Henry Ji, President and Chief Executive Officer, is scheduled to present a corporate overview at the Jefferies 2015 Immuno-Oncology Summit on Wednesday, Apr. 15 from 10:30 to 10:50 AM in the John Foster Salon at the Boston Harbor Hotel, Boston. The Company also announced that its stock has been added to the Loncar Cancer Immunotherapy Index last week. A copy of the press release is attached as Exhibit 99.1 and incorporated herein by reference.

**Item 9.01 Financial Statements and Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
99.1	Press release dated April 13, 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: April 13, 2015

SORRENTO THERAPEUTICS, INC.

By: /s/ Henry Ji

Name: Henry Ji

Title: President and Chief Executive  
Officer